France to Reimburse Weight-Loss Drugs Starting Mid-June

France will begin reimbursing weight-loss drugs such as Wegovy and Mounjaro on 15 June under its national health insurance system. The decision makes France the first country in Europe to provide permanent coverage for these medicines.

Rist said reimbursement will be set at 65 percent, but virtually all patients will receive full coverage because they have comorbidities such as hypertension or diabetes. " — Health Minister Stéphanie Rist, 28 May 2026 (Euronews) The annual cost to the state is estimated at €100 million.

Wegovy is produced by Danish pharmaceutical company Novo Nordisk, and Mounjaro is made by Eli Lilly. Both belong to the class of glucagon-like peptide-1 receptor agonists that reduce appetite. The drugs have been available by prescription in France since 2024, but until now patients paid roughly €300 per month out of pocket.

In June 2025 the government expanded prescribing authority to all physicians rather than limiting it to specialists.

According to the 2024 National Epidemiological Survey on Overweight and Obesity, about 18 percent of the French population, or roughly 10 million people, are obese. European Parliament data show that 51 percent of the EU population aged 16 and older are overweight and 17 percent are obese. As of late January, more than 70,000 patients in France were already being treated with Mounjaro.